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ABSTRACT: Imaging of hyperpolarized 13C-labeled sub-
strates has emerged as an important magnetic resonance
(MR) technique to study metabolic pathways in real time in
vivo. Even though this technique has found its way to clinical
trials, in vivo dynamic nuclear polarization is still mostly
applied in preclinical models. Its tremendous increase in
signal-to-noise ratio (SNR) overcomes the intrinsically low
MR sensitivity of the 13C nucleus and allows real-time
metabolic imaging in small structures like the mouse brain.
However, applications in brain research are limited as delivery
of hyperpolarized compounds is restrained by the blood−
brain barrier (BBB). A local noninvasive disruption of the
BBB could facilitate delivery of hyperpolarized substrates and
create opportunities to study metabolic pathways in the brain that are generally not within reach. In this work, we designed a
setup to apply BBB disruption in the mouse brain by MR-guided focused ultrasound (FUS) prior to MR imaging of 13C-
enriched hyperpolarized [1-13C]-pyruvate and its conversion to [1-13C]-lactate. To overcome partial volume issues, we
optimized a fast multigradient-echo imaging method (temporal resolution of 2.4 s) with an in-plane spatial resolution of 1.6 ×
1.6 mm2, without the need of processing large amounts of spectroscopic data. We demonstrated the feasibility to apply 13C
imaging in less than 1 h after FUS treatment and showed a locally disrupted BBB during the time window of the whole
experiment. From detected hyperpolarized pyruvate and lactate signals in both FUS-treated and untreated mice, we conclude
that even at high spatial resolution, signals from the blood compartment dominate in the 13C images, leaving the interpretation
of hyperpolarized signals in the mouse brain challenging.
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■ INTRODUCTION
13C MR spectroscopy is an established MR technique for
studying cellular metabolism. MR signals of 13C-enriched
substrates and their products are used to unravel in vitro and in
vivo metabolic pathways. However, its inherent low sensitivity
makes it a challenging technique for in vivo imaging
applications. This problem has been alleviated by dissolution
dynamic nuclear polarization (DNP), a method resulting in a
tremendously increased signal-to-noise ratio,1 allowing spatially
resolved dynamic studies of uptake and metabolic conversion
of 13C-labeled metabolites in real time. The hyperpolarized
(HP) state of the substrates that is obtained by DNP is only
short-lived and returns to thermal equilibrium with relaxation
time constant T1. Therefore, as a requirement for imaging HP
substrates, T1 relaxation times of the metabolites of interest
need to be sufficiently long to allow cellular uptake and
metabolic conversion to occur within the time the HP signal is
present.2,3 The T1 of [1-
13C]-pyruvate fulfills these require-
ments and has emerged as a typical in vivo precursor for
targeting the cell’s energy metabolism in several organs of
animals and humans.4,5
In the brain, the delivery of drugs, contrast agents, and HP
molecules can be impeded by the blood−brain barrier (BBB),
a gate keeping layer of tightly connected endothelial cells that
separate brain tissue from vasculature.6−10 Only hydrophobic
molecules <400 Da can freely pass the BBB.11 Uptake of
metabolites is based on physiochemical characteristics and is
regulated by specific facilitating transporters12 which can be
influenced by age, diet, and anesthesia levels.13−15 Previous
studies of the kinetics of pyruvate transport across the BBB
distinguished a saturable (monocarboxylate transporter
(MCT)-mediated) transport component, described by the
Michaelis−Menten equation, from a nonsaturable free
diffusion component in young rats.13,15 Transport constants
for both components appeared to be lower for pyruvate
compared to lactate, with a decreasing capacity of the saturable
carrier in animals older than 2 weeks.13 A more recent study by
Hurd et al.16 compared these pyruvate transport rates with
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labeled pyruvate to lactate fluxes and concluded that the latter
are up to 100 times faster. On the basis of this, the assumption
is made that most of the pyruvate pool in the brain
parenchyma is represented by the observed hyperpolarized
lactate pool. The remainder of the observed pyruvate signal is
then considered to be in the blood compartment.
Despite the presence of facilitating MCTs in the brain,6
there are indications that the delivery of pyruvate to the brain
parenchyma is limited,10,17,18 which makes pyruvate transport
across the BBB a subject of debate. In brain tumors, the BBB’s
restrictive aspects can be compromised due to a leaky
vasculature. However, in tumors with areas with infiltrative
growth patterns,19 blood vessels are intact and the BBB can
still be a limiting factor in pyruvate transport. Furthermore, the
BBB cannot be ignored when investigating the healthy brain.
Several methods have been proposed to chemically or
mechanically compromise the barrier function, such as
targeting endothelial surface receptors to activate transport
by means of endo- and transcytosis.20 Another approach is to
inject hypertonic solutions in order to cause endothelial cells to
shrink, stretching the connective junctions of the BBB.18,21−24
A noninvasive method that recently gained interest is based on
localized BBB disruption with focused ultrasound (FUS).25 In
short, low-intensity FUS is combined with microbubbles (an
ultrasound contrast agent) circulating in the vasculature. In the
focal spot, ultrasound waves interact with the small gas bubbles
and temporarily disassemble tight junction proteins, as proven
in preclinical studies.26,27 In this context, we speculate that a
bolus injection of HP pyruvate will saturate the rate-limited
MCT-mediated transport across the BBB and that FUS
treatment can potentially increase the transport capacity of
the nonsaturable free diffusion transport component. There-
fore, we expect an increase in pyruvate signal in the FUS-
targeted area. On the basis of the rapid conversion of HP
pyruvate to lactate and due to the low physiological blood
lactate concentration compared to the level of injected
pyruvate, which minimizes partial volume contributions, we
also expect to observe a FUS-induced HP lactate signal.
As the disruptive effect of FUS is temporary, and the
location can be precisely targeted with MR guidance, the
combination of FUS-mediated BBB-opening with imaging HP
compounds creates new opportunities to study brain
metabolism. It potentially leads to enhanced uptake of small
HP compounds in the brain and creates opportunities to study
metabolic pathways of hyperpolarized metabolites (e.g., amino
acids) for which brain access is restricted by the BBB.28 Next
to this, assessing metabolic information with DNP after FUS
treatment could also provide new insights in physiological or
metabolic effects of the FUS treatment itself.
Preclinical brain research takes advantage of the many
available mouse models for studying healthy and diseased
brains. Hence, the number of potential applications for FUS-
DNP is also high. However, it is becoming more and more
apparent that metabolic imaging of hyperpolarized compounds
in the brain is highly influenced by partial volume issues, as
addressed recently.18 Observed signals in brain parenchyma are
potentially biased or even dominated by signals from nearby
vasculature, obscuring the detection of disease-, therapy-, or
intervention-related metabolic alterations. An imaging ap-
proach with a high spatial resolution and high sensitivity is
therefore a prerequisite to study metabolism in the small
mouse brain.
In this work, we combine for the first time MR-guided
focused ultrasound-induced BBB opening with fast, dynamic,
high-resolution multigradient-echo (mGRE) 13C-MR imaging
of hyperpolarized [1-13C]-pyruvate and [1-13C]-lactate in the
mouse brain. We present a hybrid setup and show the technical
feasibility of switching rapidly between both procedures
without the need for animal repositioning. Finally, we discuss
the effect of FUS-mediated BBB disruption on dynamic 13C
MR imaging of hyperpolarized pyruvate and lactate in healthy
mice.
Figure 1. Schematic representation of the FUS-DNP setup. The injection setup is positioned behind the mouse (bottom right) and is clarified in
more detail on the top right. (a) Connection of the three-way stopcock to the tail vein. (b) Connection for the overflow tube and dissolution
collector. (c) Connected to a syringe for the injection of microbubbles or to a syringe filled with water for dissolution buffer administration. A stick
(d) is attached to the stopcock to operate the tab from outside the MR bore. The FUS transducer (e) is mounted on a movable rod for transducer
positioning. The transducer can be interchanged with the 13C coil (f). (g) Schematic cross section of the dissolution collector which replaced the
overflow tube after FUS treatment. Operation of the injection setup is further clarified in the text.
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■ RESULTS AND DISCUSSION
In order to perform 13C imaging directly after FUS treatment,
we developed a setup with an interchangeable MR-compatible
FUS transducer and 13C surface coil (Figure 1). A home-built
injection system was attached to the setup and allowed us to
administer small amounts of microbubbles, hyperpolarized
pyruvate, and MR contrast agent inside the bore of the MR
system, with a dead volume of only 50 μL. Altogether, this
enabled in-bore MR-guided FUS of the brain followed by
dynamic imaging of pyruvate and lactate with a temporal
resolution of 2.4 s, a spatial resolution of 1.6 × 1.6 mm2, and
four gradient echoes at each time point in the dynamic series.
A schematic overview of all sequential MR and FUS
procedures is shown in Figure 2.
Imaging parameters of the simultaneous dual-metabolite 13C
imaging method were optimized by simulating the cumulative
signal-to-noise ratio (SNR) as a function of the flip angle of the
excitation pulse and the number of acquisitions needed to
reconstruct multiple images at consecutive time points. We
found an optimal flip angle of 10° that provided the highest
total SNR for pyruvate over the first five imaging time points
(24 phase encoding steps per image with a repetition time
(TR) of 100 ms (Figure 3)). Phantom measurements with
13C-enriched pyruvate and lactate at thermal equilibrium
confirmed that both the 13C carrier offset and readout
bandwidth of the MRI experiment were properly chosen in
order to separate the resonances based on chemical shift
dispersion (Figure 4A). A second phantom with hyper-
polarized [1-13C]-pyruvatein absence of the enzyme lactate
dehyrogenase (LDH), needed for conversion of pyruvate to
lactatedid not show any contaminating signal at the lactate
location. Instead, due to a high SNR in the phantom, we
observed a small signal from pyruvate hydrate which can be
formed in the injection solution under alkaline conditions29
(Figure 4B). Pyruvate hydrate was not detected in vivo.
To increase SNR at each time point of the dynamic image
series, we explored two methods to combine 13C multi-
gradient-echo images that were acquired with different echo
times (TEs) into one image. The first method is a
straightforward root-mean-square (RMS) summation of four
echoes; the second method estimates the initial magnetization
at time TE = 0, using a weighted least-squares fitting algorithm
(wMt). An example of four uncombined pyruvate magnitude
images with an incrementing TE of one time point of the
dynamic series is shown in Figure 5. The combined images
were used to calculate time curves of the pyruvate and lactate
signal from a region of interest (ROI) within the brain (Figure
6). Figure 6A shows the time curve of the signal intensity of
the uncombined first echo images. B and C display time curves
of the images that were combined with the RMS method and
Figure 2. Flowchart of the in vivo FUS-DNP protocol.
Figure 3. Simulation of cumulative SNR. Total SNR of pyruvate was
simulated as a function of the flip angle and the number of excitations.
Repetition time TR was set to 100 ms; pyruvate T1 was 35 s. Every
image in the dynamic series is acquired with 24 excitations. Optimal
flip angle was estimated after the acquisition of five images
(corresponding to 120 excitations at the red line).
Figure 4. 13C GRE images with registered T2w TSE
1H image
overlays. The dashed circle indicates the true position of the sample.
(A) Phantom containing 0.5 mL [1-13C]-pyruvate and [1-13C]-lactate
at thermal equilibrium. (B) Phantom containing 1.5 mL dissolution
buffer with hyperpolarized pyruvate. Due to the high concentration,
also pyruvate hydrate (10× amplification) is detected.
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the wMt method, respectively. The average SNR of each ROI
was calculated from the time points indicated in Figure 6C.
SNR decreased when combining echoes with the RMS
method. Especially in the case of lactate, with little signal in
the third and fourth echo, the RMS-combined SNR decreased
to 0.74 when compared to the SNR of the first echo alone. The
wMt-fit method improved SNR for both lactate and pyruvate
(3% and 35% increase, respectively, when compared to first
echo SNR) and was therefore used throughout this work.
In vivo uptake and metabolic conversion of HP [1-13C]-
pyruvate was first studied in a glioma xenograft model in which
the BBB is severely disrupted by the disease. Most of the
pyruvate signal was observed in the posterior part of the brain,
which can be associated with a high vascular density in this
area. Pyruvate and lactate signals in the frontal cortex matched
with the tumor location on the T2w background image (Figure
7A), indicating that, at the location of an impaired BBB,
pyruvate locally extravasates and converts to or exchanges with
lactate, which we can detect with high-resolution HP 13C
imaging. In a second mouse model with an artificially induced
stroke no HP pyruvate or lactate signal was detected in the part
of the brain that was affected by the stroke (Figure 7B). The
absence of perfusion in the stroke-affected area prevents
Figure 5. HP 13C GRE magnitude images of the mouse brain,
acquired at different echo times (8.2, 23.9, 39.5, and 55.1 ms).
Figure 6. SNR comparison of two methods to combine multiecho GRE images. (A) ROI time curve of first echo images. The inset shows the
position of the rectangular ROI covering the whole brain. (B) ROI time curve of root-mean-square images. (C) ROI time curves of weighted M0
images calculated with a weighted least-squares fitting routine. For both methods and the first echo images, pyruvate and lactate SNR were
calculated from the mean pyruvate and lactate signal in the ROI at multiple time points (corrected for the noise level offset), divided by the
standard deviation of the noise (assessed from the same ROI in the 35 last time frames after all of the hyperpolarized signal has decayed). The SNR
of the images that were reconstructed with the wMt and the RMS method was expressed as a fold-increase compared to the SNR measured in the
first echo images. The mouse in this example received FUS treatment.
Figure 7. Models for impaired brain perfusion. (A) E478 orthotopic
human xenograft of a IDH1-mutated oligodendroglioma. The model
is known for developing leaky vessels around the tumor. A lesion in
the frontal part of the brain is marked with a red line in the anatomical
image (left). The observed enhanced pyruvate (middle) and lactate
(right) signal matched with the marked area. The pyruvate signal in
the posterior part of the brain was attributed to larger blood vessels.
(B) Mouse with stroke induced by occluding the right middle cerebral
artery for 30 min. The ischemic part is indicated with a red line.
Pyruvate signal (middle) was observed throughout the whole brain,
except in the ischemic area. No lactate was detected (right).
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injected HP pyruvate to reach this location, which indicates the
obvious dependence of detecting pyruvate on brain perfusion.
Extensive permeability, on the one hand, and almost complete
lack of perfusion, on the other, illustrate the capabilities of our
methodology in these two extreme cases.
Focused ultrasound treatment was applied in eight mice, of
which five had a successfully opened blood−brain barrier
during 13C imaging as confirmed by Gd-contrast enhanced
images (Figure 8). In all experiments, 13C imaging started
within 35 to 55 min after FUS treatment. Additional IgG
staining also confirmed successful BBB opening as the staining
of the immunoreactive endogenous IgG matched with the
targeted area. The cross-sectional diameter of the cigar-shaped
focal spot was approximately 3 mm and covered the whole
brain in the transverse direction as can be observed in the IgG-
stained slides (Figure 8C).
In the five mice with an opened BBB, most of the pyruvate
signal was observed in the posterior part of the brain. Examples
of HP pyruvate and lactate images, acquired after successful
FUS treatment, are shown in Figure 9A−D. Lactate was
detected in two out of five mice that underwent successful FUS
treatment and in two out of three mice in which FUS
treatment was not successful. We did not observe a
consistently increased pyruvate or lactate signal at the location
of the FUS target compared to the contralateral hemisphere.
Lactate signals in the posterior part of the brain matched with
the location of observed pyruvate signals. In all five control
animals, also most pyruvate was detected in the posterior part
of the brain (Figure 8E). In two out of five controls, lactate was
observed.
In a recent study, Miller et al. also investigated the limited
transport of HP pyruvate and lactate across the BBB and
concluded that the signal of endogenous lactate is below the
detection level of the HP experiment.18 This suggests that the
observed lactate signal in our nontreated animals originates
from the blood and implies that partial volume effects from
nearby vasculature have to be considered carefully.
Next to the presence of facilitating transporters and
intercellular gaps induced by ultrasound, compound delivery
can also be influenced by changes in cerebral blood flow
(CBF).13,15 As has been shown in dog and human brains in
vivo, anesthetics such as isoflurane have a vasodilative
potential.30,31 An animal study with HP pyruvate revealed
that higher doses of isoflurane resulted in increased pyruvate
signals from the cerebral blood volume, whereas levels of
metabolic products in the brain appeared to be unaffected.32
This suggests that either BBB functioning is not influenced by
isoflurane sedation or, in the case of altered pyruvate transport,
the BBB is actively keeping brain metabolite concentrations in
a steady state. FUS itself induces a temporary lowering of the
CBF. Nevertheless, blood flow is restored to pretreatment
levels within several minutes.33 Therefore, these FUS-induced
effects can be neglected at the time of our 13C imaging
experiments.
Most studies investigating kinetics of compounds in the
brain after FUS-induced BBB disruption focused on alterations
in contrast enhancement and transport rates of common MR
contrast agents of variable size. These studies reported
enhanced contrast and increased contrast agent transport
rates lasting multiple hours after applying FUS.34,35 Compound
size was inversely correlated with the half closure time t1/2 (i.e.,
the time after FUS treatment, required for the delivery of 50%
of the maximal dose).34 For Gd-containing compounds, t1/2 is
approximately 5 h. We compared Gd-contrast enhanced
Figure 8. Verification of an opened BBB at the focused ultrasound
target. (A) Aimed position of the focal spot of the FUS transducer,
projected on a T2w anatomical image. (B) Post- minus pre-contrast
T1w image showing signal enhancement in the area that was treated
with focused ultrasound (arrow). The observed in-plane cross-section
of the disrupted area was approximately 7 mm2. (C) IgG staining of a
cross-sectional slice at the height of the focal spot (dashed red line).
Brown color indicates immunoglobulin G that leaked into the tissue
from the blood. (D) IgG staining of a cross-sectional slice at the
height of the dashed green line. No leakage was observed.
Figure 9. High-resolution 13C images of HP pyruvate and lactate in
the healthy mouse brain after BBB opening. (A−D) Mice treated with
focused ultrasound prior to 13C MRI. (E) Control experiment without
FUS treatment. The first column indicates the location of the FUS
target. The second column shows T1w contrast (postpre difference)
images for BBB-opening verification. The last two columns show
single time point images with maximum HP pyruvate and lactate
signals. For displaying purposes, all lactate image intensities were
scaled 10 times compared to the corresponding pyruvate images.
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images that were acquired directly after and ∼70 min after FUS
treatment and concluded that the decrease in BBB
permeability was indeed negligible for Gd within both time
spans (Figure 10). Since in our experiments relatively large
Gd-DTPA molecules (938 Da) were able to enter brain tissue
at least up to 70 min after the FUS treatment, we argue that at
the time of the DNP experiment the smaller pyruvate
molecules (88 Da) could also pass the disrupted tight
junctions. Interestingly, in the focal spot, we observed
increasing Gd-contrast enhancement over time when sequen-
tial postcontrast images were acquired with a time lag of
several minutes (Figure 10). This is in contrast with the hyper-
intense regions around the eyes showing an immediate high-
intensity signal that decays over time.
Gd accumulation in the focal spot during the first minutes
after Gd administration has also been reported by others in
rabbits but was not observed in rats.36,37 The kinetics of Gd
uptake, directly after FUS treatment and intravenous injection
of Gd, are not fully understood. It is not straightforward to
quantify the extent of BBB opening for pyruvate from contrast-
enhanced images, and therefore current results only give a
rough indication of the transport dynamics of Gd-like large
molecules in the focal spot. When comparing these results to
the kinetics of Gd uptake and washout in tumor lesions,38,39 we
speculate that the BBB permeability increase in healthy brain
tissue by FUS is less than BBB disruptions and permeability in
brain tumors. In one of the two extreme cases in our
manuscriptthe brain tumor modelthis is what we observe
for pyruvate perfusion and lactate formation as well. For
pyruvate extravasation in FUS-mediated BBB disruption in
healthy brain tissue, nonrestricted diffusion is likely to remain
an important transport mechanism. A more rigorous
disruption, e.g. by increasing the focal area or the acoustic
pressure, could induce increased lactate formation. However,
this is at risk of hemorrhages or other tissue damage. For
mouse brain applications, we intentionally kept the size of the
focal spot small, but more than large enough in relation to the
spatial resolution of our HP MRI experiments.
Taken together, a small increase in permeability, relative to
the free diffusion component, can explain why we did not
detect small FUS-induced differences in HP pyruvate and
lactate signals within the time frame of the HP experiment.
Also when considering HP pyruvate signal accumulation over
multiple time points, we still could not distinguish FUS-
targeted from untargeted areas (Figure 11). We compared
these summed results to published micro-CT data illustrating a
dorsal whole-brain projection of the cerebral vasculature40
(Figure 11D) and observed an alignment of pyruvate signal
with densely vascularized structures in the CT image. Again,
this points to contributions from the vascular system
dominating the observed images, even at high spatial
resolution.
A recent study by Takado et al. described increased uptake
of administered HP lactate after BBB disruption with
nonlocalized ultrasound irradiation.41 In this study, whole-
brain effects of BBB opening were investigated by means of
pulse-acquire coil-localized MR spectroscopy. This whole-brain
approach demonstrates that the BBB can be opened for small
HP compounds. Since the sonicated volume is much smaller
when applying FUS, it is more challenging to detect changes in
permeability. In addition, it seems reasonable that differences
in sonication parameters also explain why the whole-brain
results were not reproduced in focal spots. High frequencies,
high acoustic pressures, and long exposure times (>300 s at
0.47 MPa) are associated with tissue damage, which may
obscure the interpretation of the effects of BBB opening.42,43
As we carefully selected our sonication frequency, exposure
time, and acoustic pressure to prevent tissue damage, brain
tissue integrity is much less challenged. As a consequence, the
change in BBB permeability might also have been smaller. On
the other hand, skull penetration is improved when sonicating
at lower frequencies. Therefore, future studies are required to
investigate the range of FUS parameters that can be applied to
induce detectable permeability changes, without causing tissue
damage.
Since we successfully imaged localized differences in
pyruvate and lactate signals that matched with a diseased
tumor or stroke area, but did not detect consistent FUS-
induced local alterations in HP signals, we argue that detection
of smaller and/or slower nuances in signal intensities requires a
higher sensitivity. The threshold at which differences become
apparent could be lowered by selecting larger voxels, leading to
higher SNR, but this inevitably introduces more partial volume
issues with vascular or adjacent tissue. In Figure 9E, tubing
from the injection setup, filled with HP pyruvate, is positioned
next to the mouse head and gives an impression to what extent
large signals can interfere with surrounding voxels at a nominal
resolution of 1.6 mm2. A possible way to gain SNR is to
optimize hyperpolarization (e.g., by using a different radical)
and to further optimize the image acquisition method. FUS-
induced compound delivery can also become more apparent if
the metabolites of interest depend more on saturable
transporters than on the diffusive component. From this
perspective, it could be interesting to image amino acids like
glutamate,44 or other metabolites that are relevant to brain
Figure 10. Gd-contrast enhanced T1w subtraction images (post-
minus pre-contrast), acquired ∼4, ∼12, and ∼35 min after Gd
administration. FUS treatment was applied ∼70 min (top row) and
12 min (bottom row) before the first T1w CE image was acquired.
The arrow indicates the location of the FUS focal spot.
Figure 11. Three representations of summed HP 13C images (5−7
time points, 2.4 s per time point). (A,B) Mice treated with FUS,
frontal right; (C) nontreated mouse. (D) Micro-CT image of a
projection of all blood vessels in the mouse brain. 13C signal
intensities align with densely vascularized areas. Reprinted with
permission from ref 40. Copyright 2013, Elsevier.
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metabolism. Nevertheless, challenges emerging from relatively
short T1 relaxation times, solubility, blood concentration
limitations, and possible toxicity have to be investigated and
overcome for these metabolites to become applicable in vivo in
humans. A recent study challenged these limitations by
investigating hyperpolarized glutamate uptake in the rat brain
after BBB disruption with a hyperosmolar agent.45 However,
the described surgical procedure to partially disrupt the BBB is
rather invasive, which points to focused ultrasound as a
valuable alternative.
Unlike most MR spectroscopic imaging approaches
presented in the literature, the use of imaging sequences for
HP metabolic imaging is less widely explored.46−50 When
interested in particular HP metabolites only, the presented
mGRE method is a fast imaging method to obtain metabolic
maps directly, without the need of postprocessing large
amounts of spectroscopic data. A single time point acquisition
at similar resolution could further improve SNR, as it allows
larger flip angles, but will be at the cost of dynamic
information. A major drawback of the GRE method is that
taking advantage of chemical shift dispersion to separate
resonances requires low readout gradient amplitudes, which
inherently dictates relatively long echo times. When aiming for
higher resolutions, even lower gradient amplitudes are
required. This opposes the usefulness of the method since at
current SNR, typical T2* decay does not allow much longer
echo times. A way to get around these limitations is by
separating resonances based on their phase difference in two or
more images with different echo times. Techniques with a
Dixon or variable projection (VARPRO) approach, as used to
separate 1H resonances of water and fat,51 can be performed
with very short echo times and at low SNR and therefore are
promising future applications of high-resolution HP imaging.
■ CONCLUSION
We showed the technical feasibility of combining MR-guided
FUS with DNP within an appropriate experimental time
window and introduced a setup that includes a mechanism to
administer small volumes of ultrasound contrast agent,
hyperpolarized pyruvate, and Gd contrast agent without air
bubbles and with minimal dead volume inside the magnet. In
contrast to most existing studies based on MR spectroscopic
imaging of HP substrates, we acquired multigradient-echo 13C
images at a high temporal and spatial resolution in mice. We
conclude that, even at a high spatial resolution, signals from
vasculature dominate the image and that changes in BBB
permeability for pyruvate and lactate were below the detection
limit of our experimental method. Although we could not
observe enhanced pyruvate uptake and/or lactate conversion
as a result of FUS treatment, our approach proposes new ways
to locally study the uptake dynamics of other hyperpolarized
metabolites for which the BBB may limit access to the brain.
■ METHODS
All experiments involving animals were conducted according to
institutional guidelines and regulations and were approved by the
Central Animal Experiments Committee (CCD) and the local animal
welfare body.
Animal Preparation. In this study, two diseased and 22 healthy
balb/c or nude balb/c mice were included, of which seven were used
to optimize the 13C imaging method, seven were used as controls for
13C MRI or FUS treatment, and eight received both FUS treatment
and 13C MRI. The two diseased animals only received HP 13C MRI.
The animals were kept under specific pathogen-free conditions in the
Central Animal Laboratory of Radboud University (Nijmegen, The
Netherlands).
A catheter was placed in the tail vein before anesthetic induction
using isoflurane gas at a 4.0% gas−air mixture. During the
preparations and experiment, the anesthetic isoflurane concentration
was adjusted to 1−2% and carried by a 2:1 mixture of medical air and
oxygen. The heads of the sedated animals that underwent BBB
disruption were shaved. During all experiments, body temperature was
measured using a rectal thermometer and maintained using heated air.
At the end of the experiment, the animals were sacrificed by cervical
dislocation. In three mice, the brain was immediately resected and
stored in formalin for immunohistochemical analysis.
Experimental Setup. The animal was placed in prone position in
the MR-compatible animal FUS system (Image Guided Therapy,
Pessac, France), and its head was fixed in a dedicated MR 1H coil. For
the BBB disruption experiments, the six-channel annular array FUS
transducer (frequency 650 kHz, focal length 30 mm, diameter 30
mm) was attached to a positioning system and coupled to the head of
the animal with an expandable balloon filled with degassed water. A
home-built injection system was developed to enable injection of
small amounts of microbubbles in the animal inside the 7T preclinical
MR system (ClinScan, Bruker BioSpin, Rheinstetten, Germany).
Following the letters and numbers in Figure 1, the setup works as
follows: The injection system consisted of a three-way stopcock
connected to the tail vein catheter (a), an overflow tube (b), and a
thin tube (0.4 mm inner diameter (i.d.)) (c) connected to a syringe
outside the MR system. The tap of the stopcock was connected to a
long stick (d) that enabled operation of the tap from outside the MR
bore. The tubing was filled with microbubbles from a syringe outside
the magnet bore (1) just before sonication, with the tap turned to the
overflow tube. Then, when the sonication started, the tap was turned
(2) and the microbubbles were injected (1) from the tubing (c) into
the tail vein (a), minimizing the dead volume substantially.
After the ultrasound procedure, the setup was taken out of the
scanner. The animal remained in place for the HP 13C MR
examination. The FUS transducer (e) was quickly removed and
replaced by a 13C MR surface coil (f), which was positioned on the
head of the animal. The overflow tube of the injection system was
replaced by a small reservoir (g) to collect the hyperpolarized buffer
solution. Outlet c was connected with 0.9 mm i.d. tubing filled with
water and an empty syringe outside the MR system. The setup was
then moved back inside the magnet and both the 1H and 13C MR
coils were tuned and matched. In order to inject the collected
hyperpolarized solution, material was sucked up with the syringe (4)
from the collector and reinjected (1) into the tail vein catheter after
switching the tap with the stick (2). With this method, the dead
volume was only 50 μL, and injection could take place within 15 s
after dissolution.
MR-Guided Local BBB Disruption. Fast gradient echo images
were acquired to localize the brain and the transducer. Next, axial T2-
weighted (T2w) and T2*-weighted (T2*w) images were obtained to
aim the focal spot of the FUS transducer at the left or right prefrontal
cortex. After adjusting the location of the FUS transducer using
Thermoguide software (Image Guided Therapy, Pessac, France), we
confirmed the absence of air bubbles between the mouse head and
transducer in coronal GRE images to ensure acoustic coupling of the
transducer with the mouse brain. Subsequently, the tubing of the
injection system was filled with microbubbles (SonoVue, Bracco
Imaging S.p.A., Italy), diluted 10 times with saline. At the start of the
sonication (10 ms bursts, burst repetition frequency 1 Hz, duration
120 s, amplitude 0.2 MPa), microbubbles were injected at 1.8 mL/kg.
At low ultrasound intensities, FUS-mediated BBB opening is
noninvasive and reversible. Ultrasound power levels are influenced
by the thickness of the skull and were carefully optimized in a pilot
study to achieve a proper penetration depth.
After the sonications, T2*w imaging was repeated to confirm no
FUS-induced microhemorrhages occurred.
Preparation of Hyperpolarized [1-13C]-Pyruvate. A total of 44
mg of isotopically enriched sodium [1-13C]-pyruvate was dissolved in
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a 160 μL mixture of D2O and deuterated ethanol (2:1), containing 30
mM 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL). All
chemicals were ordered from Sigma-Aldrich (St. Louis, MO). Small
droplets (±10 μL) of the mixture were pipetted into liquid nitrogen
to form glassed beads. The beads were collected in a Teflon container
and placed in an in-house-built polarizer as described before.52 The
sample was polarized at 1.25 K and 3.38 T using continuous
microwave irradiation at 95.05 GHz until maximum solid-state
polarization was reached (∼1 h). At the time of the 13C imaging
procedure, the polarized beads were rapidly dissolved in 4 mL of Tris-
EDTA buffer solution (10 mM/1 mM) and collected inside the MR
system, yielding a final [1-13C]-pyruvate concentration of 80 mM at a
temperature of approximately 30 °C. Within 15 s after dissolution, a
volume of 300 μL was injected in the animals using the injection
system as described above.
13C MR Imaging Method. For 13C imaging we used a fast slice
selective GRE sequence to enable simultaneous multimetabolite
imaging based on chemical shift dispersion.48,53 Due to a difference in
chemical shift (Δω), images of different resonances can be separated
by choosing proper values for the field of view (FOV) and the readout
bandwidth BW (in Hz/pixel), dependent on the width of the object
(Wobj). To prevent overlapping images the distance (Δx) between the
centers of two images with two different resonances must be larger
than Wobj:
x WobjΔ >
To enclose two images that are separated completely, and to
prevent aliasing, the width of the FOV (WFOV) must be larger than 2
× Wobj plus the additional space in between the shifted images. This
can also be expressed as
W W xFOV obj> + Δ
At a certain resolution of interest, the corresponding readout
bandwidth can be calculated according to
W
x
BW
Matrixx
FOVω= Δ ·
Δ ·
with Matrixx the image matrix size in the readout direction in pixels,
Δω the frequency difference in Hz, and WFOV and Δx in mm.
Protocol optimization led to a 13C image acquisition protocol with
a 32 × 24 imaging matrix and a FOV of 50 × 38 mm in the frequency
and phase encoding directions, respectively, yielding a nominal in-
plane resolution of 1.6 × 1.6 mm. Good separation of pyruvate and
lactate signals (Δω = 920 Hz at 7 T) was achieved by setting the
readout bandwidth to 70 Hz/pixel and placing the 13C carrier
frequency in between the pyruvate and lactate resonance frequencies
to image both metabolites with an equal but opposite shift from the
center frequency. With a TR of 100 ms and 24 phase encoding steps ,
the total acquisition time per image was 2.4 s. Per excitation, four
echoes were acquired with echo times of 8.2, 23.9, 39.5, and 55.1 ms
using monopolar or “flyback” readout gradients. Thickness of the
imaging slice was 6−8 mm. Chemical shift dispersion in the slice
selection plane was minimized by using an excitation pulse with a
bandwidth of 15 kHz.
Since the total polarization in a DNP experiment is not at
equilibrium and decays with T1 of the
13C nucleus in the substrate,
only small flip angles were applied for the multiple acquisitions
needed to form an image. The optimal flip angle for using the
hyperpolarized magnetization across multiple images was determined
by simulating the total signal-to-noise ratio (SNRT) in Matlab (The
MathWorks, Natick, MA) at a fixed TR of 100 ms as a function of the
flip angle and a variable number of excitations, assuming a T1
relaxation constant of 35 s for pyruvate, which was extrapolated
from previously reported values.54−56 Total SNR was defined as the
total signal obtained (calculated as the sum of all signals) divided by
the noise (given as the square root of the number of experiments):
M
n
SNR
sin( ) cos( ) ek
n T
T
1 0
k 1 ( TR/ )1θ θ
=
∑ [ · · · ]=
− −
with M0 the initial magnetization after hyperpolarization, n the
number of acquisitions, θ the flip angle, TR the repetition time, and
T1 the longitudinal relaxation constant.
Imaging Method Validation. The imaging method was validated
with a phantom at thermal equilibrium (no hyperpolarization),
containing [1-13C]-pyruvate and [1-13C]-lactate doped with a
TEMPOL radical to shorten the intrinsic T1 relaxation times. The
phantom was imaged with eight averages at the same resolution as the
in vivo scans, using a flip angle of 16° and a TR of 500 ms. Another
phantom was filled through the injection system with 1.5 mL of
dissolution buffer containing 80 mM hyperpolarized [1-13C]-pyruvate.
13C imaging parameters were the same as those used for 13C in vivo
measurements.
In Vivo 13C MRI. To serve as a surrogate model for a disrupted
BBB and/or increased brain perfusion, we first imaged a mouse
bearing an orthotopic human xenograft brain tumor.57 Impaired brain
perfusion was mimicked in a second mouse model with an induced
stroke.58 Next, in five healthy mice, 13C high-resolution MRI was
performed without BBB disruption and in eight mice after BBB
disruption. The 13C MRI exams started with the acquisition of
multislice T2w
1H turbo spin echo (TSE) images with a slice thickness
of 1 mm in the dorsal plane, for registration of the 13C images to the
anatomical background image. The brain was centered in a FOV of 50
× 50 mm with a matrix size of 256 × 256 points. TR was 2950 ms,
and TE was 36 ms with 37 echo trains per slice. A volume
surrounding the mouse brain was shimmed with an automated routine
followed by manual fine-tuning. The FOV for 13C MRI was
positioned exactly the same as the FOV of the reference images.
13C MRI was performed with the parameters and procedures
described above.
Image Postprocessing. Raw 13C image data were processed and
analyzed in Matlab using a dedicated in-house-built image viewer.
Background images were registered to the 13C images based on the
calculated chemical shift displacement Δx.
13C image quality was improved by zero-filling the complex data in
the frequency domain to double resolution after a 2D Hamming filter
was applied. Subsequently, magnitude images were created for further
analysis.
In order to combine the signal of the four echoes that were
acquired at each time point, we explored a weighted Mt fit (wMt) and
a root-mean-square (RMS) summation method. For the wMt fit, per
acquired time point t, the four gradient echoes were used to generate
Mt maps by pixel-wise fitting the following function to the data with a
weighted least-squares fitting algorithm:
S M(TE) et t
( TE
T2
)= · − *
with S(TE)t the pixel signal intensity of the magnitude image at echo
time TE, T2* the fitted T2* value in a specific pixel, and Mt the
magnetization at TE = 0 of each image in the dynamic series.
For the RMS method, the combined signal (SRMS,t) of each image
in the dynamic series was calculated according to
S
m
S
1
(TE )t
k
m
k tRMS,
1
2∑= ·
=
with m the number of acquired echoes and S(TEk)t the signal in a
certain pixel of the image at time t in the dynamic series at echo time
TEk.
To compare signal-to-noise ratios, a rectangular region of interest
(ROI) of the size of the brain was drawn in the anatomical image and
registered to the locations where pyruvate and lactate signals were
observed, based on their calculated chemical shift dispersion. For both
the wMt and RMS method, the SNR in these ROIs was compared
with the SNR of pyruvate and lactate in the first echo image. SNR was
defined as the mean signal intensity of all pixels from the selected ROI
at selected time points, divided by the standard deviation of all pixels
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values from that same ROI during 35 time points acquired after the
hyperpolarized signal had completely decayed. As a result of
processing images in magnitude mode, the noise level is biased,
resulting in a noise level offset. For SNR calculations, all magnitude
images were corrected for this offset by subtracting the mean noise
level which was assessed from the 35 images without a signal.
In order to further increase SNR for detecting FUS-induced signal
enhancement, we also combined wMt images of multiple time points
to obtain a single static image using a squared summation:
S S k( )
k
l
T
1
2∑= [ ]
=
with ST the total signal and k the kth image of l total images to be
summed.
Gd-Contrast Enhanced Imaging. After hyperpolarized 13C MRI
in the mice that underwent BBB disruption, T1-weighted (T1w)
images were obtained before and after administration of a gadolinium-
based MRI contrast agent (Magnevist, Bayer HealthCare Pharma-
ceuticals Inc., Wayne, NJ) at a dose of 2.5 mL/kg. As the gadolinium
particles remain in the brain parenchyma for over an hour after BBB
disruption, we chose to perform contrast-enhanced imaging at the end
of the examination, to prevent a possible effect of gadolinium on the
longitudinal relaxation of pyruvate and its metabolic products. A
hyper-intense region on postcontrast T1w images and on post- minus
pre-contrast images indicates permeability of the brain vasculature,
which was used to confirm successful disruption of the BBB. As a
control, to investigate the extent of BBB closure over time after the
HP experiment, in two mice, CE T1w images were acquired directly
after FUS treatment.
IgG-Immunostaining. As the serum antibody immunoglobulin G
(IgG) is not leaving the brain circulation when the BBB is intact, we
also confirmed BBB leakage by performing immunohistochemical
(IHC) staining of endogenous IgG on multiple 4-μm-thick sections of
formalin-fixed paraffin-embedded brain tissue of the mice that
underwent FUS-mediated BBB opening. After epitope retrieval by
boiling in citrate at pH 6.0 (Klinipath, Duiven, The Netherlands),
slides were blocked for endogenous peroxidase with 3% H2O2 and
with normal horse serum (Gibco, Waltham, MA) and incubated with
horse-antimouse IgG antibodies (H+L) (ThermoFisher, Waltham,
MA). Mouse-IgG was detected with an avidin−biotin HRP complex
kit (PK6100, VectorLabs, Burlingame, CA) and stained with DAB
(3,3′-diaminobenzidine). IHC sections were counterstained with
hematoxylin and mounted with QuickD mounting medium
(Klinipath).
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M. M. J. (2000) Noninvasive Assessment of the Functional
Neovasculature in 9L-Glioma Growing in Rat Brain by Dynamic 1
H Magnetic Resonance Imaging of Gadolinium Uptake. J. Cereb.
Blood Flow Metab. 20, 861−870.
(40) Ghanavati, S., Yu, L. X., Lerch, J. P., and Sled, J. G. (2014) A
perfusion procedure for imaging of the mouse cerebral vasculature by
X-ray micro-CT. J. Neurosci. Methods 221, 70−77.
(41) Takado, Y., Cheng, T., Bastiaansen, J. A. M., Yoshihara, H.,
Lanz, B., Mishkovsky, M., Lengacher, S., and Comment, A. (2018)
Hyperpolarized 13C MRS reveals the rate-limiting role of the blood-
brain barrier on the cerebral uptake and metabolism of L-lactate in
vivo. ACS Chem. Neurosci. 9, 2554.
(42) Hynynen, K. (2007) Focused ultrasound for blood−brain
disruption and delivery of therapeutic molecules into the brain. Expert
Opin. Drug Delivery 4, 27−35.
(43) Chopra, R., Vykhodtseva, N., and Hynynen, K. (2010)
Influence of Exposure Time and Pressure Amplitude on Blood−
Brain-Barrier Opening Using Transcranial Ultrasound Exposures. ACS
Chem. Neurosci. 1, 391−398.
(44) Gallagher, F. A., Kettunen, M. I., Day, S. E., Hu, D. E., Karlsson,
M., Gisselsson, A., Lerche, M. H., and Brindle, K. M. (2011)
Detection of tumor glutamate metabolism in vivo using13C magnetic
resonance spectroscopy and hyperpolarized [1−13C]glutamate.
Magn. Reson. Med. 66, 18−23.
(45) Mazuel, L., Schulte, R. F., Cladier̀e, A., Speźiale, C., Lagreé, M.,
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